AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01342185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medical ozone therapy with humares
Description: Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
Study NCT00278421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT01342185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diammonium glycyrrhizinate Capsules
Description: Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
Study NCT00675324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Laxabon
Description: Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
Study NCT00675324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin Energy drink
Description: 30 kcal/kg\*day five days before colonoscopy
Study NCT00278421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00193648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone (Avandia)
Description: oral drug administration
Study NCT00193648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (Humira)
Description: Injection of drug biweekly
Study NCT05816941 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Periodontal Treatment (Complete Oral Disinfection)
Description: Oral hygiene instructions followed by complete oral disinfection (removal of hard and soft deposits, scaling and root planing, mouth rinse with 0.2% chlorhexidine twice in one minute, pocket rinse with 0.2% chlorhexidine three times in ten minutes). Ultrasonic (Piezoled, KaVo) and hand instruments (Gracey curettes, Hu-Friedy, USA) were used for this purpose.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine.
Study NCT00278421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT04459780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Description: 3 biopsies on lesion skin (and one more for the first fifteen subjects in group 1)
Study NCT04459780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: One blood sample for the group 1 only.
Study NCT04382170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine sublingual film
Description: Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.
Study NCT04382170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sublingual film
Description: Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.
Study NCT04369365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 500 milligram (mg) oral Tablet
Description: weekly oral use
Study NCT04369365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: weekly oral use
Study NCT05816941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Periodontal Treatment (Complete Oral Disinfection)
Description: Oral hygiene instructions followed by complete oral disinfection (removal of hard and soft deposits, scaling and root planing, mouth rinse with 0.2% chlorhexidine twice in one minute, pocket rinse with 0.2% chlorhexidine three times in ten minutes). Ultrasonic (Piezoled, KaVo) and hand instruments (Gracey curettes, Hu-Friedy, USA) were used for this purpose.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine.
Study NCT03002415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided water intake
Description: Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention.
Study NCT03002415 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - free demand water intake
Description: Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
Study NCT00770614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate solution
Description: 154 mEq/L in dextrose and H2O
Study NCT05816941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjunctive Photodynamic Therapy
Description: Photodynamic Therapy as adjunctive treatment in pockets with PPD ≥ 5 mm. For this purpose, a Fotona XD -2 diode laser (Fotona, Ljubljana, Slovenia) with a wavelength of 810 nm, a power of 250 mW and the photosensitizing agent indocyanine green at a concentration of 1 mg/ml was used. First, the area to be irradiated was isolated, and the photosensitizing agent was applied to the periodontal pocket. After 60 seconds, the supragingival excess of the photosensitizing agent was removed by gentle rinsing with a saline solution. This was followed by irradiation for ten seconds on each side.~For the next 14 days, all patients were asked to rinse their oral cavities twice daily with 0.12% chlorhexidine.
Study NCT00085735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01675609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 drop in each eye daily for up to 35 days
Study NCT01675609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.025%
Description: 1 drop in each eye for up to 35 days
Study NCT00770614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: 0.9% sodium chloride
Study NCT05041686 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CADISS® System
Description: The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5 2.~2. Reusable stainless steel noncutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure.
Study NCT01118676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide, radiochemotherapy
Description: Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.~The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).~After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy.
Study NCT00770614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00600574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: weekly pool physiotherapy with muscle stretching
Study NCT00600574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: weekly pool physiotherapy with Ai Chi movements during a 6 months period
Study NCT01520935 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).~Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed.
Study NCT03657927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC videolaryngoscope
Description: An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
Study NCT03657927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC videolaryngoscope
Description: An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
Study NCT01269294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 2 capsules of 75 mg once daily for 7 days in Treatment A
Study NCT01269294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo for TMC435
Description: 4 placebo capsules once daily for 7 days in Treatment C
Study NCT01269294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
Study NCT01269294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo for TMC435
Description: 2 placebo capsules once daily for 7 days in Treatment A
Study NCT01269294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: 1 tablet of 400 mg on Day 7 of Treatment C
Study NCT04917549 — intervention group
Intervention type: OTHER
Intervention: detection of oral lesions
Description: oral lesions in patient diagnosed with COVID-19
Study NCT02765555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: Single dose
Study NCT01269294 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo for moxifloxacin
Description: 1 placebo tablet on Day 7 of Treatments A, B and D
Study NCT01269294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TMC435
Description: 4 placebo capsules once daily for 7 days in Treatment D
Study NCT03328065 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: Semi-directed interviews, recorded and transcribed for analysis
Study NCT02864511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nefertiti lift
Study NCT02150577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence Based Quality Improvement
Description: Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
Study NCT03328065 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: economic and psycho-social questionnaires
Study NCT01621633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Study NCT04658355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: 4% Chlorhexidine Gluconate vaginal cleansing solution as a surgical preparation.
Study NCT04658355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine
Description: 10% povidone-iodine vaginal cleansing solution as a surgical preparation.
Study NCT03669302 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Robotic gait training
Description: Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
Study NCT03669302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic gait training and low-frequency transspinal stimulation
Description: Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a single pulse at 0.3 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
Study NCT03669302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic gait training and high-frequency transspinal stimulation
Description: Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
Study NCT04575558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and Azithromycin
Description: Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
Study NCT04575558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine and Azithromycin
Description: Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
Study NCT02442973 — intervention group
Intervention type: PROCEDURE
Intervention: Control group (CG): standard practice
Description: Standard practice group
Study NCT02442973 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound group (UG):
Description: SpineView3D™ anatomical scouting approach
Study NCT02442973 — intervention group
Intervention type: DEVICE
Intervention: Accuro SpineView3D™
Description: subject will be scanned with 'Accuro SpineView3D
Study NCT04105374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Flucytosine
Description: Given PO
Study NCT04105374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-100A Device
Description: Receive Optune device
Study NCT04105374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04105374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04105374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04105374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04105374 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation
Study NCT04105374 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation
Study NCT04105374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study NCT04105374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT04105374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study NCT04105374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery
Study NCT04105374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vocimagene Amiretrorepvec
Description: Given via intracranial injection
Study NCT06351995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Neostigmine and Glycopyrrolate
Description: Intravenous or transdermal
Study NCT06351995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Box by Dynatronics
Description: Electric field conducting drugs through the skin without compromising its integrity
Study NCT02699892 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab will be administered at the discretion of treating physician according to approved label. Protocol does not specify/enforce the criteria for initiation of treatment with rituximab and procedure of the infusion of rituximab.
Study NCT03561909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Platelet transfusion
Description: Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.
Study NCT01178060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Heart Attack and Stroke Risk
Description: Personalized assessment of heart attack and stroke risk based on 10yr predictors with individual risk factors.
Study NCT01178060 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Education
Description: Patients received a general handout describing risk factors for heart attack and stroke.
Study NCT00607308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365
Description: Single dose of 0.1 mg/kg IV on Day 1
Study NCT00607308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365
Description: Single dose of 0.5 mg/kg IV on Day 1
Study NCT00607308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365
Description: Single dose of 1 mg/kg IV on Day 1
Study NCT00607308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365
Description: Single dose of 5 mg/kg IV on Day 1
Study NCT00607308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo IV on Day 1
Study NCT00607308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365
Description: Single dose of 10 mg/kg IV on Day 1
Study NCT03627221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music listening and social network
Description: The 12-week combination of music care and social network program consists of three parts: sleep related variables assessment and monitoring, sleep management education and outcome evaluation. Participants in the intervention group will receive weekly online (social network) education and music listening interventions for 12 weeks provided by the PI.
Study NCT02879565 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Semi structured interviews + EEG exams
Study NCT03086733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
Study NCT03716869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal Screening Arm
Description: Students with PHQ-9 score >10, corresponding to a positive MDD screen, will proceed through the same SAP triage process as students referred by traditional means.~SAP triage will determine MDD identification. As SAP triage is not diagnostic, MDD identification is based on SAP recommendations for MDD related school or community services.~Treatment engagement will be tracked per current SAP processes.~To immediately identify and address suicidal intent, the survey will flag a positive response to PHQ-9 question 9 in real time. A suicidal student would proceed directly to management through the school crisis plan.~Students in the intervention arm will also be tracked for behavior concerning for MDD at any point in the school year prompting SAP triage referral.
Study NCT01256073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2101
Description: IPH2101 fully human anti-KIR monoclonal antibody
Study NCT03646851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Questionnaries
Description: patients will have to do a sputum and to complete some questionnaries
Study NCT00283114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lintuzumab
Description: 1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
Study NCT00071071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-CD4
Description: HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.
Study NCT00071071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-CD4
Description: HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.